Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic … – PR Newswire (press release)

Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic
PR Newswire (press release)
Statistically, regadenoson was found to be not significantly different from placebo in causing a >15% decrease in FEV1 in patients with asthma (p = 0.1451)

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *